Peli BioThermal opens India service centre

Peli BioThermal wraps up a year of webinars

Peli BioThermal has announced the opening of its latest service centre located in India. The new service centre is based in Ahmedabad, a major manufacturing hub for pharma companies in the Western part of India.

The new site is a full service network station offering conditioning and refurbishment services for Peli BioThermal’s Crēdo Cargo and Crēdo Xtreme bulk shippers to meet the region’s rising requirement for the company’s Crēdo on Demand rental program.

“This is the latest development of our rapidly expanding Crēdo on Demand rental program,” said Dominic Hyde, Peli BioThermal vice president – global services. “Ahmedabad is a key site where more than eight of India’s largest pharma companies have multiple plants operating, which are all major exporters to markets in Europe and the U.S.

“Our market-leading, high-performing products will be readily available for our customers in the region, which is an area of significant growth for multiple Clinical Research Organisations conducting clinical trials, another area of growth in India. Peli BioThermal’s new India service centre is the latest location in our growing global drop points, service centres and network stations, supporting rental programs to more than 100 locations, as we continue to extensively expand our infrastructure worldwide to better meet the complex needs of our international customers.”

An increasing number of leading pharmaceutical companies are located in Ahmedabad including Astra Zeneca, Swiss Pharma and Torrent Pharma. Served by an international airport, Ahmedabad is an important economic hub where numerous pharma companies have R&D facilities based to introduce new products to the market.

It is estimated the state of Gujarat, where Ahmedabad is located, accounts for approximately 30% of the country’s pharmaceutical production and exports. Within the global pharma market India provides more than 50% of the worldwide requirement for various vaccines and 40% of the demand for generic products in the United States.